Advertisement

Decellularization in Heart Valve Tissue Engineering

  • Katherine M. Copeland
  • Bo Wang
  • Xiaodan Shi
  • Dan T. Simionescu
  • Yi Hong
  • Pietro Bajona
  • Michael S. Sacks
  • Jun LiaoEmail author
Chapter

Abstract

Annually, over 50,000 deaths are attributed to heart valve disease (HVD) in the United States. The most common treatment for HVD, such as stenosis and regurgitation, is total valve replacement using mechanical and bioprosthetic heart valves, which often results in subsequent surgery to replace failed implants. For the pediatric population especially, a viable valve implant with the potential to repair, remodel, and grow within the patient is a great clinical need. Recent research has demonstrated that tissue-engineered heart valves (TEHV) have the potential to deliver a viable valve replacement, which is constructed with scaffolds and functional cells. Acellular heart valve (HV) scaffolds obtained by decellularization, biological polymer scaffolds, and synthetic polymer scaffolds have been widely used for TEHV fabrication, each having advantages and disadvantages. In this chapter, we focus on TEHV via a decellularization approach and provide a systematic review covering (1) the concepts of decellularization and current decellularization methods, (2) a comparative study showing how the ultrastructure and biomechanics of acellular HV scaffolds were affected by different decellularization methods, (3) the cell sources and bioreactor systems for TEHV reseeding, conditioning, and integrity testing, and (4) the current accomplishments of HV decellularization in animal studies and clinical trials and the challenges in moving this approach toward clinical applications.

Keywords

Heart valves Decellularization Aortic valve leaflets Acellular valve scaffolds Extracellular matrix Trilayered structure Collagen Elastin Proteoglycans Tissue engineering Bioreactors Valve replacements 

Notes

Acknowledgments

This work is supported in part by AHA BGIA-0565346U, GRNT17150041, NIH 1R01EB022018-01, 1R56HL130950-01, 1R15HL140503, T32HL134613, and NSF CAREER #1554835. The authors also thank the support from the Competitiveness Operational Programme 2014–2020, ID P_37_673, MySMIS code: 103431, contract 50/05.09.2016 and the Harriet and Jerry Dempsey Bioengineering Professorship.

References

  1. 1.
    Mozaffarian D, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):447–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Davlouros PA, et al. Transcatheter aortic valve replacement and stroke: a comprehensive review. J Geriatr Cardiol. 2018;15(1):95.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Stewart BF, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;29(3):630–4.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Mozaffarian D, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–60.Google Scholar
  5. 5.
    Hammermeister K, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36(4):1152–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Tillquist MN, Maddox TM. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Prefer Adherence. 2011;5:91–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Frater R, et al. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis. 1998;7(1):48–53.PubMedGoogle Scholar
  8. 8.
    Marchand MA, et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann Thorac Surg. 2001;71(5):S236–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Bloomfield P, et al. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med. 1991;324(9):573–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaneko T, Cohn LH, Aranki SF. Tissue valve is the preferred option for patients aged 60 and older. Circulation. 2013;128(12):1365–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Vesely I. Heart valve tissue engineering. Circ Res. 2005;97(8):743–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Delgado V, et al. Successful deployment of a transcatheter aortic valve in bicuspid aortic stenosis. Circ Cardiovasc Imaging. 2009;2(2):e12–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Henaine R, et al. Valve replacement in children: a challenge for a whole life. Arch Cardiovasc Dis. 2012;105(10):517–28.PubMedCrossRefGoogle Scholar
  14. 14.
    Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79(3):1072–80.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Manji RA, et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation. 2006;114(4):318–27.PubMedCrossRefGoogle Scholar
  16. 16.
    Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet. 1967;2(7523):956–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Charitos EI, et al. Reoperations on the pulmonary autograft and pulmonary homograft after the Ross procedure: an update on the German Dutch Ross Registry. J Thorac Cardiovasc Surg. 2012;144(4):813–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Lam MT, Wu JC. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev Cardiovasc Ther. 2012;10(8):1039–49.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Simionescu D, et al. Form follows function: advances in trilayered structure replication for aortic heart valve tissue engineering. J Healthcare Eng. 2012;3(2):179–202.CrossRefGoogle Scholar
  20. 20.
    Engelmayr GC, et al. The independent role of cyclic flexure in the early in vitro development of an engineered heart valve tissue. Biomaterials. 2005;26(2):175–87.CrossRefGoogle Scholar
  21. 21.
    Hoerstrup SP, et al. New pulsatile bioreactor for in vitro formation of tissue engineered heart valves. Tissue Eng. 2000;6(1):75–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ramamurthi A, Vesely I. Evaluation of the matrix-synthesis potential of crosslinked hyaluronan gels for tissue engineering of aortic heart valves. Biomaterials. 2005;26(9):999–1010.PubMedCrossRefGoogle Scholar
  23. 23.
    Meyer U, et al. Fundamentals of tissue engineering and regenerative medicine. Berlin: Springer; 2009.CrossRefGoogle Scholar
  24. 24.
    Bouten CV, et al. Substrates for cardiovascular tissue engineering. Adv Drug Deliv Rev. 2011;63(4–5):221–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Rippel RA, Ghanbari H, Seifalian AM. Tissue-engineered heart valve: future of cardiac surgery. World J Surg. 2012;36(7):1581–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Baraki H, et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials. 2009;30(31):6240–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Sacks MS, Schoen FJ, Mayer JE Jr. Bioengineering challenges for heart valve tissue engineering. Annu Rev Biomed Eng. 2009;11:289–313.PubMedCrossRefGoogle Scholar
  28. 28.
    Vesely I, Noseworthy R. Micromechanics of the fibrosa and the ventricularis in aortic valve leaflets. J Biomech. 1992;25(1):101–13.CrossRefGoogle Scholar
  29. 29.
    Brazile B, et al. On the bending properties of porcine mitral, tricuspid, aortic, and pulmonary valve leaflets. J Long-Term Eff Med Implants. 2015;25(1–2):41–53.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Tomasek JJ, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349–63.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Stella JA, Sacks MS. The digital leaflet: quantitative image analysis and 3-D digital reconstruction of the aortic valve leaflet. In: ASME 2007 summer bioengineering conference. American Society of Mechanical Engineers; 2007.Google Scholar
  32. 32.
    Adham M, et al. Mechanical characteristics of fresh and frozen human descending thoracic aorta. J Surg Res. 1996;64(1):32–4.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Isenberg BC, Williams C, Tranquillo RT. Small-diameter artificial arteries engineered in vitro. Circ Res. 2006;98(1):25–35.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Filip DA, Radu A, Simionescu M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res. 1986;59(3):310–20.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007;171(5):1407–18.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Merryman WD, et al. Viscoelastic properties of the aortic valve interstitial cell. J Biomech Eng. 2009;131(4):041005.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 1999;250(2):273–83.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Butcher JT, Nerem RM. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng. 2006;12(4):905–15.CrossRefGoogle Scholar
  39. 39.
    Aikawa E, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113(10):1344–52.CrossRefGoogle Scholar
  40. 40.
    Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials. 2006;27(19):3675–83.PubMedGoogle Scholar
  41. 41.
    Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011;32(12):3233–43.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Neumann A, et al. Early systemic cellular immune response in children and young adults receiving decellularized fresh allografts for pulmonary valve replacement. Tissue Eng Part A. 2014;20(5–6):1003–11.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Lichtenberg A, et al. Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation. 2006;114(1 Suppl):I559–65.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Dohmen PM, et al. Ross operation with a tissue-engineered heart valve. Ann Thorac Surg. 2002;74(5):1438–42.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Liao J, Joyce EM, Sacks MS. Effects of decellularization on the mechanical and structural properties of the porcine aortic valve leaflet. Biomaterials. 2008;29(8):1065–74.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Zhou J, et al. Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials. 2010;31(9):2549–54.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Dainese L, et al. Heart valve engineering: decellularized aortic homograft seeded with human cardiac stromal cells. J Heart Valve Dis. 2012;21(1):125–34.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Cigliano A, et al. Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium. Biochem Res Int. 2012;2012:979351.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Rieder E, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg. 2004;127(2):399–405.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Lehr EJ, et al. Decellularization reduces immunogenicity of sheep pulmonary artery vascular patches. J Thorac Cardiovasc Surg. 2011;141(4):1056–62.PubMedCrossRefGoogle Scholar
  51. 51.
    Dong X, et al. RGD-modified acellular bovine pericardium as a bioprosthetic scaffold for tissue engineering. J Mater Sci Mater Med. 2009;20(11):2327–36.PubMedCrossRefGoogle Scholar
  52. 52.
    Prasertsung I, et al. Development of acellular dermis from porcine skin using periodic pressurized technique. J Biomed Mater Res B Appl Biomater. 2008;85(1):210–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Reing JE, et al. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. Biomaterials. 2010;31(33):8626–33.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Gorschewsky O, et al. Quantitative analysis of biochemical characteristics of bone-patellar tendon-bone allografts. Biomed Mater Eng. 2005;15(6):403–11.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Cox B, Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc. 2006;1(4):1872–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Xu CC, Chan RW, Tirunagari N. A biodegradable, acellular xenogeneic scaffold for regeneration of the vocal fold lamina propria. Tissue Eng. 2007;13(3):551–66.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Petersen TH, et al. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538–41.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hudson TW, Liu SY, Schmidt CE. Engineering an improved acellular nerve graft via optimized chemical processing. Tissue Eng. 2004;10(9–10):1346–58.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Cebotari S, et al. Detergent decellularization of heart valves for tissue engineering: toxicological effects of residual detergents on human endothelial cells. Artif Organs. 2010;34(3):206–10.CrossRefGoogle Scholar
  60. 60.
    Meyer SR, et al. Comparison of aortic valve allograft decellularization techniques in the rat. J Biomed Mater Res A. 2006;79(2):254–62.PubMedCrossRefGoogle Scholar
  61. 61.
    Lumpkins SB, Pierre N, McFetridge PS. A mechanical evaluation of three decellularization methods in the design of a xenogeneic scaffold for tissue engineering the temporomandibular joint disc. Acta Biomater. 2008;4(4):808–16.PubMedCrossRefGoogle Scholar
  62. 62.
    Grauss RW, et al. Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularisation methods. Eur J Cardiothorac Surg. 2005;27(4):566–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Fung Y-C. Biomechanics: mechanical properties of living tissues. New York: Springer Science & Business Media; 2013.Google Scholar
  64. 64.
    Liao J, et al. The intrinsic fatigue mechanism of the porcine aortic valve extracellular matrix. Cardiovasc Eng Technol. 2012;3(1):62–72.CrossRefGoogle Scholar
  65. 65.
    Dohmen PM, et al. Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg. 2007;84(3):729–36.PubMedCrossRefGoogle Scholar
  66. 66.
    Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Hoerstrup SP, et al. Functional living trileaflet heart valves grown in vitro. Circulation. 2000;102(19 Suppl 3):III44–9.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Latif N, et al. Characterization of structural and signaling molecules by human valve interstitial cells and comparison to human mesenchymal stem cells. J Heart Valve Dis. 2007;16(1):56–66.PubMedGoogle Scholar
  69. 69.
    Rotmans JI, et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation. 2005;112(1):12–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Zhang S, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014;111(48):17266–71.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Sodian R, et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010;89(3):819–28.PubMedCrossRefGoogle Scholar
  72. 72.
    Schmidt D, et al. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg. 2004;78(6):2094–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Schmidt D, et al. Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur J Cardiothorac Surg. 2005;27(5):795–800.PubMedCrossRefGoogle Scholar
  74. 74.
    Schmidt D, et al. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng. 2006;12(11):3223–32.PubMedCrossRefGoogle Scholar
  75. 75.
    Schmidt D, et al. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation. 2006;114(1 Suppl):I125–31.PubMedGoogle Scholar
  76. 76.
    Corselli M, et al. Clinical scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor cells is associated with high incidence of karyotype aberrations. Exp Hematol. 2008;36(3):340–9.PubMedCrossRefGoogle Scholar
  77. 77.
    De Coppi P, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1):100–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Schmidt D, et al. Cryopreserved amniotic fluid-derived cells: a lifelong autologous fetal stem cell source for heart valve tissue engineering. J Heart Valve Dis. 2008;17(4):446–55; discussion 455.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Prusa A-R, Hengstschlager M. Amniotic fluid cells and human stem cell research: a new connection. Med Sci Monit. 2002;8(11):RA253–7.PubMedGoogle Scholar
  80. 80.
    Tsai MS, et al. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004;19(6):1450–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Siepe M, et al. Stem cells used for cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2008;34(2):242–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Vander Roest MJ, Merryman WD. A developmental approach to induced pluripotent stem cells-based tissue engineered heart valves. Future Medicine. 2017;13:1–4.Google Scholar
  83. 83.
    Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol. 2004;22(2):80–6.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Bancroft GN, Sikavitsas VI, Mikos AG. Design of a flow perfusion bioreactor system for bone tissue-engineering applications. Tissue Eng. 2003;9(3):549–54.PubMedCrossRefGoogle Scholar
  85. 85.
    Pörtner R, et al. Bioreactor design for tissue engineering. J Biosci Bioeng. 2005;100(3):235–45.PubMedCrossRefGoogle Scholar
  86. 86.
    Sierad LN, et al. Design and testing of a pulsatile conditioning system for dynamic endothelialization of polyphenol-stabilized tissue engineered heart valves. Cardiovasc Eng Technol. 2010;1(2):138–53.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Mol A, et al. The relevance of large strains in functional tissue engineering of heart valves. Thorac Cardiovasc Surg. 2003;51(2):78–83.PubMedCrossRefGoogle Scholar
  88. 88.
    Engelmayr GC Jr, et al. A novel bioreactor for the dynamic flexural stimulation of tissue engineered heart valve biomaterials. Biomaterials. 2003;24(14):2523–32.CrossRefGoogle Scholar
  89. 89.
    Engelmayr GC Jr, et al. A novel flex-stretch-flow bioreactor for the study of engineered heart valve tissue mechanobiology. Ann Biomed Eng. 2008;36(5):700–12.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Weston MW, Yoganathan AP. Biosynthetic activity in heart valve leaflets in response to in vitro flow environments. Ann Biomed Eng. 2001;29(9):752–63.CrossRefGoogle Scholar
  91. 91.
    Zeltinger J, et al. Development and characterization of tissue-engineered aortic valves. Tissue Eng. 2001;7(1):9–22.PubMedCrossRefGoogle Scholar
  92. 92.
    Mol A, et al. Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann Biomed Eng. 2005;33(12):1778–88.PubMedCrossRefGoogle Scholar
  93. 93.
    Cebotari S, et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation. 2006;114(1 Suppl):I132–7.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Schmidt D, et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol. 2010;56(6):510–20.PubMedCrossRefGoogle Scholar
  95. 95.
    Syedain ZH, et al. Implantation of a tissue-engineered heart valve from human fibroblasts exhibiting short term function in the sheep pulmonary artery. Cardiovasc Eng Technol. 2011;2(2):101–12.CrossRefGoogle Scholar
  96. 96.
    Dohmen PM, et al. Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg. 2011;92(4):1308–14.PubMedCrossRefGoogle Scholar
  97. 97.
    da Costa FD, et al. The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg. 2010;90(6):1854–60.PubMedCrossRefGoogle Scholar
  98. 98.
    Simon P, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT® in pediatric patients. Eur J Cardiothorac Surg. 2003;23(6):1002–6.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Bayrak A, et al. Human immune responses to porcine xenogeneic matrices and their extracellular matrix constituents in vitro. Biomaterials. 2010;31(14):3793–803.PubMedCrossRefGoogle Scholar
  100. 100.
    Leyh RG, et al. In vivo repopulation of xenogeneic and allogeneic acellular valve matrix conduits in the pulmonary circulation. Ann Thorac Surg. 2003;75(5):1457–63.PubMedCrossRefGoogle Scholar
  101. 101.
    Dohmen PM, Konertz W. Results with decellularized xenografts. Circ Res. 2006;99(4):e10.PubMedCrossRefGoogle Scholar
  102. 102.
    Mol A, et al. Tissue engineering of heart valves: advances and current challenges. Expert Rev Med Devices. 2009;6(3):259–75.PubMedCrossRefGoogle Scholar
  103. 103.
    Schoen FJ, Levy RJ. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res A. 1999;47(4):439–65.CrossRefGoogle Scholar
  104. 104.
    Mendelson K, Schoen FJ. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng. 2006;34(12):1799–819.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med. 2011;17(8):424–32.PubMedCrossRefGoogle Scholar
  106. 106.
    Haupt J, et al. Detergent-based decellularization strategy preserves macro- and microstructure of heart valves. Interact Cardiovasc Thorac Surg. 2018;26(2):230–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Lu X, et al. Crosslinking effect of nordihydroguaiaretic acid (NDGA) on decellularized heart valve scaffold for tissue engineering. J Mater Sci Mater Med. 2010;21(2):473–80.CrossRefGoogle Scholar
  108. 108.
    Tedder ME, et al. Stabilized collagen scaffolds for heart valve tissue engineering. Tissue Eng Part A. 2009;15(6):1257–68.PubMedCrossRefGoogle Scholar
  109. 109.
    Deborde C, et al. Stabilized collagen and elastin-based scaffolds for mitral valve tissue engineering. Tissue Eng A. 2016;22(21–22):1241–51.CrossRefGoogle Scholar
  110. 110.
    Stamm C, et al. Biomatrix/polymer composite material for heart valve tissue engineering. Ann Thorac Surg. 2004;78(6):2084–92; discussion 2092–3.PubMedCrossRefGoogle Scholar
  111. 111.
    Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005;23(1):47–55.PubMedCrossRefGoogle Scholar
  112. 112.
    Ouyang H, et al. [Research on application of modified polyethylene glycol hydrogels in the construction of tissue engineered heart valve]. Zhonghua wai ke za zhi [Chin J Surg]. 2008;46(22):1723–6.Google Scholar
  113. 113.
    Schoen FJ. Heart valve tissue engineering: quo vadis? Curr Opin Biotechnol. 2011;22(5):698–705.PubMedCrossRefGoogle Scholar
  114. 114.
    Hjortnaes J, et al. Translating autologous heart valve tissue engineering from bench to bed. Tissue Eng Part B Rev. 2009;15(3):307–17.PubMedCrossRefGoogle Scholar
  115. 115.
    Bouten CV, Driessen-Mol A, Baaijens FP. In situ heart valve tissue engineering: simple devices, smart materials, complex knowledge. Expert Rev Med Devices. 2012;9(5):453–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Katherine M. Copeland
    • 1
  • Bo Wang
    • 2
  • Xiaodan Shi
    • 1
  • Dan T. Simionescu
    • 3
  • Yi Hong
    • 1
  • Pietro Bajona
    • 4
  • Michael S. Sacks
    • 5
  • Jun Liao
    • 6
    Email author
  1. 1.Department of BioengineeringUniversity of Texas at ArlingtonArlingtonUSA
  2. 2.College of Science, Mathematics and TechnologyAlabama State UniversityMontgomeryUSA
  3. 3.Department of BioengineeringClemson UniversityClemsonUSA
  4. 4.Department of Cardiovascular and Thoracic SurgeryUniversity of Texas Southwestern Medical CenterDallasUSA
  5. 5.The Oden Institute and the Department of Biomedical EngineeringThe University of Texas at AustinAustinUSA
  6. 6.Tissue Biomechanics and Bioengineering Laboratory, The Department of BioengineeringThe University of Texas at ArlingtonArlingtonUSA

Personalised recommendations